Long heralded by global sponsors as cost-effective alternatives to western markets, the BRIC nations – Brazil, Russia, India, and China – are experiencing declines in the number of clinical drug trials initiated. But the benefits of conducting clinical research in these countries remain as attractive as ever. Beth
Nuskey of Thomson Reuters explains how BRIC markets have been working diligently on strengthening regulatory frameworks in recent years.
 
https://www.jforcs.com/7/wp-content/uploads/2014/08/Regulatory.pdf